Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lecanemab, an antibody targeting Amyloid-β.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Orilanolimab, an antibody targeting FcRn.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Batoclimab, an antibody targeting FcRn.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nipocalimab, an antibody targeting FcRn.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rozanolixizumab, an antibody targeting FcRn.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bezlotoxumab, an antibody targeting Clostridioides difficile toxin B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lirentelimab, an antibody targeting Siglec-8.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Barzolvolimab, an antibody targeting KIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etrolizumab, an antibody targeting β7 integrin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Natalizumab, an antibody targeting α4 integrin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vedolizumab, an antibody targeting α4β7 integrin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obexelimab, a bispecific antibody targeting CD19/FcγRIIb.